RSS Search

News  Feeds  Tags  Search Shortcuts

FeedsFarm.com > T1653 Mutation in the Box [alpha] Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection

T1653 Mutation in the Box [alpha] Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection

30th Nov 2005, 00:48 GMT

Background. Most patients with chronic hepatitis B virus infection become carriers of inactive virus after hepatitis B e antigen seroconversion; however, a subgroup of patients have persistent abnormal transaminase levels and develop hepatocellular carcinoma after seroconversion. Methods. In an age-matched case-control study, 40 carriers of inactive virus (mean [FORMULA] deviation [SD], 50.9 ± 11.1 years), 40 patients with chronic hepatitis (mean [FORMULA], 50.2 ± 8.9 years), and 40 patients with hepatocellular carcinoma (mean [FORMULA], 50.7 ± 9.4 years) who were infected with hepatitis B virus genotype C and had test results positive for antibody to hepatitis B e antigen were analyzed. Results. The prevalence of T1653 in the box α was significantly higher among patients with hepatocellular carcinoma than among carriers of inactive virus who did not have hepatocellular carcinoma (70% vs. 25%; [FORMULA]) or chronic hepatitis (70% vs. 35%; [FORMULA]). Mutations in the basic core promoter region (T1762/A1764) were frequently found in all groups, regardless of clinical status (in 77.5% of carriers of inactive virus, 77.5% of patients with chronic hepatitis, and 90% of patients with hepatocellular carcinoma). In the multivariate analysis, the presence of T1653, an alanine aminotransferase level of 37 U/L, and a platelet count of

View full story at www.journals.uchicago.edu

T1653 Mutation in the Box [alpha] Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection related news:

Latest news from Clin Infect Dis Latest Articles: